

Eileen O Dareng

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7565055/publications.pdf>

Version: 2024-02-01

47
papers

829
citations

623734

14
h-index

526287

27
g-index

51
all docs

51
docs citations

51
times ranked

1454
citing authors

#	ARTICLE	IF	CITATIONS
1	High-depth African genomes inform human migration and health. <i>Nature</i> , 2020, 586, 741-748.	27.8	197
2	Prevalent high-risk HPV infection and vaginal microbiota in Nigerian women. <i>Epidemiology and Infection</i> , 2016, 144, 123-137.	2.1	104
3	Qualitative study of barriers to cervical cancer screening among Nigerian women. <i>BMJ Open</i> , 2016, 6, e008533.	1.9	82
4	Age-specific prevalence of human papilloma virus infection among Nigerian women. <i>BMC Public Health</i> , 2014, 14, 656.	2.9	50
5	HIV associated high-risk HPV infection among Nigerian women. <i>BMC Infectious Diseases</i> , 2013, 13, 521.	2.9	44
6	Persistent Low-Risk and High-Risk Human Papillomavirus Infections of the Uterine Cervix in HIV-Negative and HIV-Positive Women. <i>Frontiers in Public Health</i> , 2017, 5, 178.	2.7	37
7	Implementation of genomics research in Africa: challenges and recommendations. <i>Global Health Action</i> , 2018, 11, 1419033.	1.9	36
8	Cohort Profile: African Collaborative Center for Microbiome and Genomics Researchâ€™s (ACCME's) Human Papillomavirus (HPV) and Cervical Cancer Study. <i>International Journal of Epidemiology</i> , 2017, 46, 1745-1745j.	1.9	30
9	Recurrence of cervical intraepithelial lesions after thermo-coagulation in HIV-positive and HIV-negative Nigerian women. <i>BMC Women's Health</i> , 2016, 16, 25.	2.0	24
10	Polygenic risk modeling for prediction of epithelial ovarian cancer risk. <i>European Journal of Human Genetics</i> , 2022, 30, 349-362.	2.8	23
11	Influence of Spirituality and Modesty on Acceptance of Self-Sampling for Cervical Cancer Screening. <i>PLoS ONE</i> , 2015, 10, e0141679.	2.5	20
12	Prevalence and incidence of genital warts and cervical Human Papillomavirus infections in Nigerian women. <i>BMC Infectious Diseases</i> , 2019, 19, 27.	2.9	20
13	Burden of Cancers Attributable to Infectious Agents in Nigeria: 2012â€™2014. <i>Frontiers in Oncology</i> , 2016, 6, 216.	2.8	18
14	P-B31â€™ Cohort profile. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 71, 87.	2.1	18
15	RPS19 and TYMS SNPs and Prevalent High Risk Human Papilloma Virus Infection in Nigerian Women. <i>PLoS ONE</i> , 2013, 8, e66930.	2.5	17
16	Ovarian Cancer Risk Variants Are Enriched in Histotype-Specific Enhancers and Disrupt Transcription Factor Binding Sites. <i>American Journal of Human Genetics</i> , 2020, 107, 622-635.	6.2	14
17	Vaginal microbiota diversity and paucity of <i>Lactobacillus</i> species are associated with persistent hrHPV infection in HIV negative but not in HIV positive women. <i>Scientific Reports</i> , 2020, 10, 19095.	3.3	14
18	The burden of HPV associated cancers in two regions in Nigeria 2012â€™2014. <i>Cancer Epidemiology</i> , 2016, 45, 91-97.	1.9	13

#	ARTICLE	IF	CITATIONS
19	Clearance of Type-Specific, Low-Risk, and High-Risk Cervical Human Papillomavirus Infections in HIV-Negative and HIV-Positive Women. <i>Journal of Global Oncology</i> , 2018, 4, JGO.17.00129.	0.5	12
20	Testâ€“Retest Reliability of Self-Reported Sexual Behavior History in Urbanized Nigerian Women. <i>Frontiers in Public Health</i> , 2017, 5, 172.	2.7	10
21	Attitude to Human Papillomavirus Deoxyribonucleic Acid-Based Cervical Cancer Screening in Antenatal Care in Nigeria: A Qualitative Study. <i>Frontiers in Public Health</i> , 2017, 5, 226.	2.7	9
22	Cancers Attributable to Alcohol Consumption in Nigeria: 2012â€“2014. <i>Frontiers in Oncology</i> , 2017, 7, 183.	2.8	9
23	Age, HIV status, and research context determined attrition in a longitudinal cohort in Nigeria. <i>Journal of Clinical Epidemiology</i> , 2018, 100, 32-43.	5.0	7
24	Secular trend in interobserver agreement of VIA diagnosis for cervical cancer screening in Nigeria. <i>PLoS ONE</i> , 2018, 13, e0208531.	2.5	3
25	HIV-associated high-risk HPV infection in Nigerian women.. <i>Journal of Clinical Oncology</i> , 2013, 31, 1576-1576.	1.6	3
26	P-B25â€“fInfluence of spirituality and modesty on acceptance of self sampling for cervical cancer screening. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 71, 84.	2.1	1
27	P-B29â€“fBarriers to cervical cancer screening among Nigerian women. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 71, 86.	2.1	1
28	Incidence, Persistence, and Determinants of Human Papillomavirus: A Prospective Cohort Study of HIV-Negative Nigerian Women. <i>Journal of Global Oncology</i> , 2017, 3, 39s-40s.	0.5	1
29	Cohort profile: African Collaborative Center for Microbiome and Genomics Research (ACCME) study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 5524-5524.	1.6	1
30	Incidence, clearance and predictors of type-specific HPV infection among Nigerian women.. <i>Journal of Clinical Oncology</i> , 2016, 34, e17001-e17001.	1.6	1
31	Abstract 2588: Increased risk of prevalent high risk human papillomavirus infection in <i>Lactobacillus iners</i> rich microbiota in Nigerian women.. <i>Cancer Research</i> , 2013, 73, 2588-2588.	0.9	1
32	chromMAGMA: regulatory element-centric interrogation of risk variants. <i>Life Science Alliance</i> , 2022, 5, e202201446.	2.8	1
33	P-A4â€“fPrevalence and Incidence of genital warts among women in Nigeria. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 67, 77.	2.1	0
34	P-C2â€“fPersistence of high risk Human Papillomavirus infection among Nigerian women. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 67, 84.	2.1	0
35	Reliability of Self Reported Sexual Behaviour History. <i>Journal of Global Oncology</i> , 2016, 2, 79s-79s.	0.5	0
36	Risk, Persistence and Multiplicity of HPV Infections among HIV Negative and HIV Positive Nigerian Women. <i>Journal of Global Oncology</i> , 2016, 2, 38s-39s.	0.5	0

#	ARTICLE	IF	CITATIONS
37	P-B17â€fPersistent human papillomavirus infection in a cohort of Nigerian women. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 71, 80.	2.1	0
38	P-B16â€fThe Burden of human papilloma virus associated cancers in Nigeria 2012â€“2014. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 71, 79.	2.1	0
39	P-B30â€fAssociation between HIV and persistent HPV infections among Nigerian women. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 71, 86.	2.1	0
40	P-B24â€fFactors associated with attrition in a prospective cohort study in Nigeria. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 71, 83.	2.1	0
41	P-B22â€fRecurrence of cervical intraepithelial lesions after Thermo-coagulation in HIV-positive and HIV-negative Nigerian Women. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 71, 82.	2.1	0
42	P-B12â€fComparison of HPV genotyping using roche linear array with Spf10-Deia Lipa 25 Version 1 in Nigerian women presenting for cervical cancer screening. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 71, 77.	2.1	0
43	P-B20â€fEvaluation of the feasibility of incorporating HPV DNA- based cervical cancer screening into routine antenatal care in Nigeria. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 71, 81.	2.1	0
44	P-B33â€fHPV Persistence and age-specific type distribution among Nigerian women. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 71, 88.	2.1	0
45	PE-1â€fVaginal microbiota composition and persistent high-risk HPV infection in HIV negative and HIV positive women. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 81, 65-65.	2.1	0
46	Risk, persistence, and multiplicity of HPV infections among HIV-negative and HIV-positive Nigerian women.. Journal of Clinical Oncology, 2016, 34, 1565-1565.	1.6	0
47	Incidence, persistence and determinants of human papillomavirus: A prospective cohort study of 10,000 HIV-negative Nigerian women.. Journal of Clinical Oncology, 2017, 35, 1510-1510.	1.6	0